Epidarex Capital

Epidarex Capital is a venture capital firm specializing in early stage, startup, and growth capital investments. The firm provides equity capital to young companies including University Spin-outs and under-ventured markets. It seeks to invest in all the life science and health technology companies with a focus on biotechnology, medical devices, pharmaceuticals, personalized medicine and diagnostics, as well as healthcare information technology and services. The firm seeks to invest in the United States, the United Kingdom and Europe focusing on Scotland. Epidarex Capital was formerly known as Rock Spring Ventures. Epidarex Capital is based in Bethesda, Maryland with additional offices in Edinburgh, United Kingdom; and Tokyo, Japan.
MC

Mary Canning

Principal

SD

Sinclair Dunlop

Managing Partner

Peter Finan

Partner

IK

Isao Kikuchi

Director

DM

Daniel Marshall

Senior Associate

MM

Matthew Miessau

Associate

ER

Elizabeth Roper

Partner

KS

Kyparissia Sirinakis

Managing Partner

HS

Henning Steinhagen Ph.D.

Venture Partner

TW

Tracy Weightman

Associate

39 past transactions

Slate Bio

Seed Round in 2021
Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics.

RapidPulse

Series A in 2021
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

RapidPulse

Series A in 2022
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Macomics Ltd

Seed Round in 2021
Macomics Ltd develops immunotherapies that helps to modulate macrophages and increase body’s immune system against tumours. The company was incorporated in 2018 and is based in Edinburgh, United Kingdom.

Caldan Therapeutics

Series A in 2015
Caldan Therapeutics Ltd is a spinout company from the University of Glasgow (UofG) and the University of Southern Denmark (SDU), developing novel therapeutics targeting modulators of free fatty acid receptors, for metabolic disease including Type 2 Diabetes (T2D) and other indications. The spinout opportunity has arisen from a long term collaboration between Professor Graeme Milligan (UofG) and Professor Trond Ulven (SDU). Free fatty acid receptors have recently emerged as exciting targets for T2D, due to their involvement in multiple aspects of T2D pathophysiology. There may also be potential to explore other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.
Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

IGEM Therapeutics

Series B in 2022
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

Transine Therapeutics

Seed Round in 2022
Transine Therapeutics

Lunac Therapeutics

Series A in 2019
Lunac Therapeutics is a UK-based drug discovery company.

Dunad Therapeutics

Series A in 2021
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Dunad Therapeutics

Seed Round in 2021
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Topas Therapeutics GmbH

Series B in 2021
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Theolytics

Series A in 2021
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.

Lunac Therapeutics

Venture Round in 2021
Lunac Therapeutics is a UK-based drug discovery company.

RapidPulse

Venture Round in 2022
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

IGEM Therapeutics

Series A in 2017
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Clyde Biosciences Ltd.

Series A in 2015
Clyde Biosciences Ltd. offers developmental drug testing solutions that provide clients with insights into the working mechanisms and actions of drugs in research and development, as well as enable them to evaluate the drug toxicity. It develops cellOPTIQ, an optical action potential assay providing clients with an understanding of the effects of drug compounds on human cells to address unmet needs in testing cardiotoxicity risk in new and existing drugs. The company also develops XTENDSR, a solution that provides clients with direct measurements of drug induced changes on cardiac sarcoplasmic reticulum function. It serves pharmaceutical and biotechnology companies in the United Kingdom and internationally. Clyde Biosciences Ltd. was founded in 2012 and is based in Glasgow, United Kingdom.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

NodThera Limited

Series A in 2018
NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.
Funderbeam Ou operates investing and trading platform for investors to buy and sell equity stakes in private companies. It operates a funding and trading platform for high-growth private companies. The company’s platform helps founders raise funds and provides access liquidity to early stage equity investors. The company was founded in 2013 and is based in Tallinn, Estonia with an additional office in London, United Kingdom.

Macomics Ltd

Seed Round in 2020
Macomics Ltd develops immunotherapies that helps to modulate macrophages and increase body’s immune system against tumours. The company was incorporated in 2018 and is based in Edinburgh, United Kingdom.

Libra Therapeutics

Series A in 2020
Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.

Eternygen

Series A in 2017
Eternygen GmbH, a biotechnology company, engages in the research, development, and marketing of NaCT inhibitors for the treatment of dietary-related metabolic diseases. The company was incorporated in 2012 and is based in Berlin, Germany with an additional office in the United Kingdom.

Topas Therapeutics GmbH

Series B in 2020
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

SIRAKOSS Ltd.

Series A in 2014
SIRAKOSS Ltd., a medical device company, develops synthetic bone graft substitutes for the treatment of bone defects and fusions. Its products include MaxSi graft granules; and MaxSi graft granules in a putty system that are shaped by the surgeon and administered directly at the defect site. The company was founded in 2010 and is based in Edinburgh, United Kingdom. As of November 5, 2020, SIRAKOSS Ltd. operates as a subsidiary of OssDsign AB (publ).
AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effects of high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Enterprise Therapeutics Ltd

Venture Round in 2016
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

IGEM Therapeutics

Series A in 2018
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Edinburgh Molecular Imaging Limited operates as a biotechnology company focusing on enabling image-guided therapy to detect, diagnose, and monitor diseases. It offers molecular imaging technology based on fluorescent imaging to detect disease in real-time during interventional procedures, including surgery and accurate treatment. The company discovers and develops small molecules and peptides that conjugate with fluorescent dyes, cancerous cells, and other diseased tissue. Its optical imaging platform detects disease in real-time during interventional procedures. Edinburgh Molecular Imaging Limited was founded in 2014 and is based in Edinburgh, United Kingdom.

Mironid Limited

Series A in 2016
Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.

Confluence Life Sciences

Series A in 2014
Confluence Life Sciences, Inc. operates as a KINect technology based company that focuses on drug design to identify mechanistically novel drugs. It develops a portfolio of projects to address unmet medical needs in caner and chronic inflammatory diseases. The company focuses on designing and developing kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in the modulation of chronic inflammation. Its KINect technology platform enables the identification and development of new protein kinase drugs. Confluence Life Sciences, Inc. was founded in 2010 and is based in Saint Louis, Missouri. As of August 3, 2017, Confluence Life Sciences, Inc. operates as a subsidiary of Aclaris Life Sciences, Inc.

NodThera Limited

Series B in 2020
NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

Confluence Life Sciences

Series B in 2015
Confluence Life Sciences, Inc. operates as a KINect technology based company that focuses on drug design to identify mechanistically novel drugs. It develops a portfolio of projects to address unmet medical needs in caner and chronic inflammatory diseases. The company focuses on designing and developing kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in the modulation of chronic inflammation. Its KINect technology platform enables the identification and development of new protein kinase drugs. Confluence Life Sciences, Inc. was founded in 2010 and is based in Saint Louis, Missouri. As of August 3, 2017, Confluence Life Sciences, Inc. operates as a subsidiary of Aclaris Life Sciences, Inc.

Topas Therapeutics GmbH

Series A in 2016
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.